Literature DB >> 16868053

Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration.

K Boelaert1, J Horacek, R L Holder, J C Watkinson, M C Sheppard, J A Franklyn.   

Abstract

CONTEXT: Thyroid nodules and goiter are common, and fine-needle aspiration biopsy (FNAB) is the first investigation of choice in distinguishing benign from malignant disease.
OBJECTIVE: The objective of the study was to assess whether simple clinical and biochemical parameters can predict the likelihood of thyroid malignancy in subjects undergoing FNAB.
DESIGN: The design was a prospective cohort.
SETTING: The study was conducted at a single secondary/tertiary care clinic. PARTICIPANTS: One thousand five hundred consecutive patients without overt thyroid dysfunction (1304 females and 196 males, mean age 47.8 yr) presenting with palpable thyroid enlargement between 1984 and 2002 were evaluated by FNAB of the thyroid. INTERVENTION(S): There were no interventions. MAIN OUTCOME MEASURES: Goiter type was assessed clinically and classified as diffuse in 183, multinodular in 456, or solitary nodule in 861 cases. Serum TSH concentration at presentation was measured in a sensitive assay in patients presenting after 1988 (n = 1183). The final cytological or histological diagnosis was determined after surgery (n = 553) or a minimum 2-yr clinical follow-up period (mean 9.5 yr, range 2-18 yr).
RESULTS: The overall sensitivity and specificity of FNAB in predicting malignancy were 88 and 84%, respectively. The risk of diagnosis of malignancy rose in parallel with the serum TSH at presentation, with significant increases evident in patients with serum TSH greater than 0.9 mU/liter, compared with those with lower TSH. Binary logistic regression analysis revealed significantly increased adjusted odds ratios (AORs) for the diagnosis of malignancy in subjects with serum TSH 1.0-1.7 mU/liter, compared with TSH less than 0.4 mU/liter [AOR 2.72, 95% confidence interval (CI) 1.02-7.27, P = 0.046], with further increases evident in those with TSH 1.8-5.5 mU/liter (AOR 3.88, 95% CI 1.48-10.19, P = 0.006, compared with TSH < 0.4 mU/liter) and greater than 5.5 mU/liter (AOR 11.18, 95% CI 3.23-8.63, P < 0.001, compared with TSH < 0.4 mU/liter). Males (AOR 1.8, 95% CI 1.04-3.1, P = 0.04), younger patients (AOR 1.1, 95% CI 1.01-1.15, P = 0.025), and those with clinically solitary nodules (AOR 2.53, 95% CI 1.5-4.28, P = 0.001) were also at increased risk. Based on these findings, a formula to predict the risk of the diagnosis of thyroid malignancy in individual patients, taking into account their gender, age, goiter type determined clinically, and serum TSH, was calculated.
CONCLUSIONS: The risk of malignancy in a thyroid nodule increases with serum TSH concentrations within the normal range. In addition to patient's gender, age, and goiter type, the serum TSH concentration at presentation is an independent predictor of the presence of thyroid malignancy. We propose that these simple clinical and biochemical factors can serve as an adjunct to FNAB in predicting risk of malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868053     DOI: 10.1210/jc.2006-0527

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  121 in total

1.  Occupational pesticide exposure and subclinical hypothyroidism among male pesticide applicators.

Authors:  Catherine C Lerro; Laura E Beane Freeman; Curt T DellaValle; Muhammad G Kibriya; Briseis Aschebrook-Kilfoy; Farzana Jasmine; Stella Koutros; Christine G Parks; Dale P Sandler; Michael C R Alavanja; Jonathan N Hofmann; Mary H Ward
Journal:  Occup Environ Med       Date:  2017-08-03       Impact factor: 4.402

2.  Oxidative stress: a new risk factor for thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2012-01-09       Impact factor: 5.678

3.  The relationship between glucose metabolism disorders and malignant thyroid disease.

Authors:  Ayse Ocak Duran; Cüneyd Anil; Alptekin Gursoy; Aslı Nar; Ozden Altundag; Neslihan Bascil Tutuncu
Journal:  Int J Clin Oncol       Date:  2012-06-30       Impact factor: 3.402

4.  Prevalence of Cancer in Patients with Thyroid Nodules in the Island of Cyprus: Predictive Value of Ultrasound Features and Thyroid Autoimmune Status.

Authors:  Irini S Hadjisavva; Roberto Dina; Michael A Talias; Panayiotis A Economides
Journal:  Eur Thyroid J       Date:  2015-05-30

5.  Predictors of malignancy in patients with cytologically suspicious thyroid nodules.

Authors:  M Regina Castro; Rachel P Espiritu; Rebecca S Bahn; Michael R Henry; Hossein Gharib; Pedro J Caraballo; John C Morris
Journal:  Thyroid       Date:  2011-10-18       Impact factor: 6.568

6.  Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor.

Authors:  Haitao Zheng; Jie Xu; Shaolong Hao; Xincheng Liu; Jinrao Ning; Xicheng Song; Lixin Jiang; Zongying Liu
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

Review 7.  Thyroid Autoimmunity and Thyroid Cancer: Review Focused on Cytological Studies.

Authors:  Francesco Boi; Fabiana Pani; Stefano Mariotti
Journal:  Eur Thyroid J       Date:  2017-04-24

8.  Sleep disturbance and incidence of thyroid cancer in postmenopausal women the Women's Health Initiative.

Authors:  Juhua Luo; Megan Sands; Jean Wactawski-Wende; Yiqing Song; Karen L Margolis
Journal:  Am J Epidemiol       Date:  2012-12-05       Impact factor: 4.897

Review 9.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

10.  Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States.

Authors:  Cari M Kitahara; Martha S Linet; Laura E Beane Freeman; David P Check; Timothy R Church; Yikyung Park; Mark P Purdue; Catherine Schairer; Amy Berrington de González
Journal:  Cancer Causes Control       Date:  2012-07-29       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.